Pipeline

February 29, 2020
Company Drug/Device Medical Condition Status
Moderna mRNA-1273 coronavirus vials shipped to NIH for use in phase 1 trial
Magenta Therapeutics MGTA-145 stem cell mobilization needed completion of dosing in phase 1 trial
Pandion Therapeutics PT101 autoimmune diseases dosing of first subject in phase 1 trial
Actinium Pharmaceuticals Actimab-A 7+3 acute myeloid leukemia phase 1 trial dose escalation
Cyclo Therapeutics Trappsol Cyclo Niemann-Pick disease Type C Alzheimer’s disease patient enrollment completed for phase 1 trial
Abivax ABX196 inflammatory diseases, viral diseases and cancer dosing of first patient in phase 1/2 trial
BeiGene

SpringWorks

(Mapkure) 		BGB-3245 advanced or refractory solid tumors initiation of phase 1 trial
Anokion KAN-101 celiac disease initiation of patient dosing in phase 1 trial
Neurimmune NI006 ATTR cardiomyopathy initiation of phase 1 trial
Inflazome Somalix harmful inflammation completion of phase 1 trial
Sojournix SJX-653 menopausal hot flashes initiation of phase 2 trial
Ascentage Pharma APG-1387 advanced pancreatic cancer approval of phase 1/2b trial
CytomX Therapeutics

Bristol-Myers Squibb		 BMS-986249 alone and in combination with nivolumab selected advanced solid tumors initiated phase 2 expansion of phase 1/2a trial
Axcella AXA1665-002 complex diseases completed enrollment in phase 2 trial
Fulcrum Therapeutics losmapimod facioscapulohumeral muscular dystrophy completed patient enrollment in phase 2b trial
iTeos Therapeutics EOS-448 advanced cancers enrolled first patient in phase 1/2 trial
Antibe Therapeutics ATB-346 osteoarthritis pain last patient enrolled in phase 2b trial
Exelixis CABOMETYX (cabozantinib) radioactive iodine-refractory differentiated thyroid cancer phase 3 trial enrolling the first 100 of 300 patients at 150 sites globally
Marinus Pharmaceuticals oral ganaxolone CDKL5 Deficiency Disorder in children and young adults phase 3 trial initiated enrolling 100 patients
Gilead Sciences remdesivir COVID-19 two phase 3 trials initiated
PolyPid D-PLEX100 prevention of sternal wound infection after cardiac surgery phase 3 trial initiated enrolling first patient
Noxopharm Veyonda soft tissue sarcomas IND approved by the FDA
Translate Bio MRT5005 cystic fibrosis Fast-Track designation granted by the FDA
Debiopharm Debio 1143 confirmed diagnosis of previously untreated, unresectable locally advanced squamous cell carcinoma of the head and neck Breakthrough Therapy designation granted by the FDA
Lundbeck VYEPTI (eptinezumab-jjmr) migraine approved by the FDA
Eli Lilly Trulicity (dulaglutide) major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular (CV) disease or multiple cardiovascular risk factors new indication approved by the FDA
Seqirus FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted) seasonal influenza in individuals age 65 and older approved by the FDA
Teva Respiratory ArmonAir Digihaler (fluticasone propionate) Inhalation Powder) asthma approved by the FDA
Esperion Nexletol (bempedoic acid) adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C approved by the FDA
Esperion Nexlizet (bempedoic acid and ezetimibe) adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C approved by the FDA
Puma Biotechnology neratinib in combination with capecitabine adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting supplemental NDA approved by the FDA
Acacia Pharma BARHEMSY (amisulpride injection) Postoperative Nausea and Vomiting approved by the FDA

 

Upcoming Events

Featured Products

Featured Stories

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here